Why I'm Not Arbing The Fresenius / Akorn Deal | RSS News Feed
Why I'm Not Arbing The Fresenius / Akorn Deal - Latest News
Why I'm Not Arbing The Fresenius / Akorn Deal
I am not interested in risk-arbing this deal at the current risk/reward profile (6.25% in 1 year). The deal continues to make sense from a strategic perspective for Fresenius, but I think Akorn has significant downside if the deal breaks. The chart on the ... read more
Germany’s Fresenius, US-based Akorn at odds over merger deal
Fresenius said Sunday it would terminate the year-old deal to acquire Akorn, based in Lake Forest, Illinois, citing its “failure to fulfill several closing conditions.” Akorn replied that it “categorically disagrees” with Fresenius’ accusations ... read more
Can Akorn Win Its Fight Against Fresenius?
Akorn Inc. (NASDAQ: AKRX) shares were crushed on Monday (although not as bad as at Prothena ... but who will win is still yet to be seen. Fresenius said Sunday it would terminate the $4.3 billion deal to acquire Akorn as the result of its “failure ... read more
Looking for another news?
Fresenius picks up M&A pace with Akorn, Merck KGaA deals
Berenberg analyst Tom Jones said the price tag of 12.4 times Akorn's core earnings (adjusted EBITDA) estimate for 2017 should not "give ... GMT (3.50 am ET), broadly in line with the European healthcare index (.SXDP). For the Merck deal, Fresenius will ... read more
SA Interview: Event-Driven Investing With Donostia
Donostia: For the merger arb strategy, I focus mainly on announced deals ... I am of the view that Fresenius has not made the case a MAC has occurred and will have difficulty doing so. Fresenius is alleging widespread fraud (Case No. 2018-0300-JTL, Akorn ... read more
Today’s Research Reports on Stocks to Watch: Merck and Akorn
According to Fresenius, its outside experts had found “material breaches” of U.S. FDA standards while reviewing Akorn’s operations. It was last April when the deal was announced ... RDInvesting has not been compensated; directly or indirectly ... read more
Could Data Breaches Break Up the Akorn Aquisition?
This isn’t the first time that Akorn has faced concerns regarding its security, but this could be the costliest. Essentially, Fresenius is conducting an independent investigation into “alleged breaches” at Akorn. These breaches have to deal with FDA ... read more